Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) COO Sells $126,673.94 in Stock

Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) COO Peter Radovich sold 2,627 shares of the business’s stock in a transaction that occurred on Monday, February 3rd. The stock was sold at an average price of $48.22, for a total transaction of $126,673.94. Following the completion of the sale, the chief operating officer now directly owns 26,961 shares of the company’s stock, valued at $1,300,059.42. This represents a 8.88 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website.

Peter Radovich also recently made the following trade(s):

• On Friday, January 24th, Peter Radovich sold 3,177 shares of Mirum Pharmaceuticals stock. The stock was sold at an average price of $47.92, for a total transaction of $152,241.84.
• On Tuesday, January 7th, Peter Radovich sold 1,998 shares of Mirum Pharmaceuticals stock. The stock was sold at an average price of $42.82, for a total transaction of $85,554.36.

Mirum Pharmaceuticals Trading Down 2.0 %

Shares of MIRM stock opened at $51.23 on Friday. The stock has a market cap of $2.46 billion, a price-to-earnings ratio of -25.36 and a beta of 0.96. The company has a debt-to-equity ratio of 1.33, a quick ratio of 3.15 and a current ratio of 3.34. The firm has a fifty day moving average of $44.61 and a 200-day moving average of $42.17. Mirum Pharmaceuticals, Inc. has a 52-week low of $23.14 and a 52-week high of $53.49.

Mirum Pharmaceuticals (NASDAQ:MIRM) last announced its earnings results on Tuesday, November 12th. The company reported ($0.30) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.45) by $0.15. The business had revenue of $90.38 million during the quarter, compared to analysts’ expectations of $81.99 million. Mirum Pharmaceuticals had a negative net margin of 31.69% and a negative return on equity of 41.22%. The firm’s revenue for the quarter was up 89.4% on a year-over-year basis. During the same quarter last year, the company posted ($0.57) EPS. On average, equities research analysts forecast that Mirum Pharmaceuticals, Inc. will post -1.44 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Mirum Pharmaceuticals

A number of hedge funds have recently added to or reduced their stakes in MIRM. Lord Abbett & CO. LLC bought a new stake in Mirum Pharmaceuticals during the 3rd quarter worth about $28,913,000. Loomis Sayles & Co. L P bought a new position in Mirum Pharmaceuticals during the 3rd quarter worth approximately $19,473,000. State Street Corp raised its holdings in Mirum Pharmaceuticals by 19.9% during the 3rd quarter. State Street Corp now owns 1,793,728 shares of the company’s stock worth $69,955,000 after buying an additional 297,511 shares during the period. Erste Asset Management GmbH acquired a new stake in Mirum Pharmaceuticals during the 3rd quarter worth approximately $10,136,000. Finally, Raymond James Financial Inc. acquired a new stake in Mirum Pharmaceuticals during the 4th quarter worth approximately $10,611,000.

Analyst Ratings Changes

Several analysts recently issued reports on the stock. Robert W. Baird upped their price objective on shares of Mirum Pharmaceuticals from $44.00 to $50.00 and gave the stock an “outperform” rating in a report on Wednesday, November 13th. Citigroup upped their price objective on shares of Mirum Pharmaceuticals from $65.00 to $68.00 and gave the stock a “buy” rating in a report on Wednesday, November 13th. HC Wainwright reaffirmed a “buy” rating and set a $66.00 price objective on shares of Mirum Pharmaceuticals in a report on Wednesday, November 13th. Finally, Leerink Partners upped their price objective on shares of Mirum Pharmaceuticals from $47.00 to $49.00 and gave the stock an “outperform” rating in a report on Thursday, October 17th. Ten investment analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat, Mirum Pharmaceuticals has an average rating of “Buy” and an average target price of $57.10.

About Mirum Pharmaceuticals

Mirum Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. Its lead product candidate is LIVMARLI (maralixibat), an orally administered and minimally absorbed ileal bile acid transporter (IBAT) inhibitor that is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome in the United States and internationally.